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Objective/Background.—Insomnia commonly co-occurs with chronic migraines (CM). Non-pharmacological treatments for 
insomnia in CM patients remain understudied. This is a proof-of-concept study, which aims to evaluate the feasibility, acceptabil-
ity, and preliminary efficacy of a digital cognitive behavioral therapy for insomnia (dCBT-I) for individuals with CM and 
 insomnia (CM-I) in the United States.
Methods.—We recruited 42 females with CM-I symptoms from a U.S.-based observational cohort and from the general 
population via advertisements. Within a multiple baseline design, participants were randomized to receive dCBT-I after 2, 4, or 
6  weeks of completing baseline sleep diaries. DCBT-I was scrutinized against benchmarks for completion rates (≥90% to com-
plete dCBT-I), acceptability (≥80% to find dCBT-I acceptable), and posttreatment changes in insomnia symptoms (≥50% indi-
cating a clinically relevant improvement in their insomnia symptoms). As a secondary measure, we also reported percentage of 
individuals reverting to episodic migraines.
Results.—Out of 42 randomized, 35 (83.3%) completed dCBT-I within the 12 weeks provided. Of these completers, 33 (94.3%) 
reported being satisfied (n  =  16) or very satisfied (n  =  17) with treatment. Additionally, 65.7% of completers responded to treat-
ment as per universally accepted criteria for insomnia. Lastly, 34% of completers reverted from CM to episodic migraine.
Conclusion.—This study provides evidence for the feasibility and acceptability of dCBT-I in patients with CM-I complaints. 
Effects of improving insomnia and migraines were suggested. These results indicate that a randomized controlled trial is needed 
to determine the efficacy of dCBT-I in CM patients.
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INTRODUCTION
Insomnia symptoms such as difficulties initiat-
ing or maintaining sleep are a frequent complaint in 
patients with chronic migraines (CM).1-9 A bidirec-
tional relationship between CM and insomnia (CM-I) 
has been proposed10,11 and explanations have varied 
from common pathophysiological mechanisms12,13 to 
biobehavioral processes.14 Ong and Park published 
a conceptual model describing the potential mecha-
nisms underlying this bidirectional relationship.14 The 
behaviors adopted to cope with migraine attacks (nap-
ping, oversleeping, caffeine, and medication intake) are 
known to reduce the likelihood of rapid sleep onset at 
night,15 reduce sleep homeostasis, and disrupt circa-
dian rhythms.16,17 These changes in turn can lead to an 
increased propensity to future headache attacks.1,18-25 
This increased propensity leads to further engagement 
in coping behaviors, which triggers a vicious cycle 
 between headache attacks and chronic insomnia.
Treatment of insomnia might offer an opportunity 
to interrupt this vicious cycle and there are a number 
of convincing arguments why cognitive behavior ther-
apy for insomnia (CBT-I) should be the treatment of 
choice. First, insomnia is a treatable condition,26,27 and 
CBT-I is recommended as first line treatment,28 even 
when it occurs in the context of a medical condition 
such as chronic pain.29,30 Second, the coping strategies 
outlined in the biobehavioral model,14 are behaviors 
that can be modified through CBT-I.31 Third, CM 
patients are often less open to polypharmacological 
options,32 leading to patients being potentially more 
accepting of non-pharmacological treatments for 
insomnia.
To our knowledge, only 2 studies have tested cogni-
tive and behavioral interventions for insomnia in adults 
with CM.33,34 Smitherman and colleagues34 evaluated 
a 3-sesion face-to-face behavioral treatment for in-
somnia for patients with CM and comorbid insomnia, 
which included stimulus control and sleep restriction 
instructions. The intervention was associated with 
significantly greater improvement in sleep efficiency 
and sleep quality. Calhoun and Ford33 randomized 43 
women with CM to a sleep hygiene intervention or pla-
cebo control group with the aim to revert chronicity 
by improving sleep. After 6 weeks of the intervention, 
remission to episodic migraine was substantially 
greater in the treatment than in a placebo control 
condition (35 vs 0%). Six weeks after completing the 
behavioral treatments for insomnia, the authors re-
ported a reduction in headache frequency twice the 
effect seen in the placebo control condition, which in-
cluded lifestyle changes only (48% reduction vs 25% 
reduction). Both of these clinical trials used face-to-
face  behavioral interventions. Unfortunately, such 
face-to-face interventions are time intensive and costly. 
CBT-I sessions usually last between 60 and 90 minutes, 
with 4-8 sessions needed to cover all components of 
the treatment. The inaccessibility of CBT-I has also 
been highlighted,35,36 thus, many patients with CM will 
not have access to face-to-face CBT-I. A final chal-
lenge is the debilitating nature and unpredictability of 
migraines, which might make regular attendance and en-
gagement with a face-to-face CBT-I program difficult.
Fortunately, over the last few decades, so-called 
minimal contact therapies have been developed, lim-
iting the amount of additional burden of migraine 
treatments.37,38 Digital therapies are a type of minimal 
contact therapy, because individuals are able to access 
the intervention content in their own home and com-
plete it at their own pace. In the last decade, there has 
been an explosion of available digital CBT-I (dCBT-I) 
programs that have proven effective, with effect sizes 
comparable to that of face-to-face therapy.39-41 The 
unique aspects of dCBT-I could make it very suitable for 
individuals with CM.42 DCBT-I is flexible, scalable, and 
accessible; the patient can access it at their own conve-
nience, in their own home, or when away. Furthermore, 
migraine patients could avoid the exposure to the clin-
ical environment with bright lights and noise that can 
exacerbate a migraine attack. Most likely a result of the 
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debilitating nature of CM,32,43-48 individuals with head-
aches are more likely to miss health appointments than 
other pain disorders.49 Digital forms of therapy could 
thus facilitate engagement in this population.
However, it is equally important to consider the po-
tential challenges of dCBT-I for CM patients. For ex-
ample, increased screen time could lead to an increase 
in headaches or migraines, as reported in other studies.50 
Furthermore, CBT-I includes temporary sleep depriva-
tion as part of sleep restriction therapy, which in itself  
may increase headaches/migraines.21 Indeed, in par-
ticipants without migraine, an increase in headaches 
and/or migraines have been reported as a side effect of 
dCBT-I.51,52 Completing a fully automated, digital treat-
ment without guidance from a health care provider might 
prove challenging and lead to increased dropout rates. 
These are real concerns for the implementation of digital 
therapy in this population, and with this proof-of-con-
cept study, we are able to evaluate whether these concerns 
would prevent users from engaging in the program. The 
aims of this proof-of-concept study were to establish fea-
sibility and acceptability of dCBT-I in patients with CM 
and preliminary efficacy of this treatment in improving 
insomnia symptoms and migraines. We set benchmarks 
to inform future refinement of dCBT-I for patients with 
CM-I.
METHODS
Participants.—Participants were recruited from 
2 sources. The first subset included a pool of partic-
ipants who completed a case-control observational 
study;53 that included an assessment of sleep and circa-
dian phase in women with migraines. The second sub-
set of participants were individuals with CM-I, who 
were prospectively recruited through (1) referrals from 
patients who presented to the Department of Neuro-
logical Sciences at Rush University Medical Center; (2) 
referrals from other health care providers; (3) adver-
tisements posted around the medical Centre where the 
research was conducted, on public transportation (eg, 
buses and trains), and on community bulletin boards 
(online and physical); (4) research listservs; (5) news-
letters; and (6) word of mouth. We recruited until 
May 2016 toward our minimum target sample size of 
20. While no formal power calculation was conduct-
ed, this sample size was expected to be meaningful 
to evaluate feasibility and acceptability of the treat-
ment.54 We included women 18  years or above, who 
had endorsed symptoms of insomnia, defined as a to-
tal score ≥11 on the Insomnia Severity Index (ISI).55 
This validated cutoff  score is recommended for clinical 
trials on insomnia.55 Furthermore, individuals had to 
meet criteria for CM, which was defined as ≥15 head-
ache days per month for ≥3 months with ≥8 of those 
days characterized as migraines days56 and assessed 
through the Structured Diagnostic Interview and 
Headache checklist (SDIH-R,57). We only included fe-
males because of the high prevalence of women in both 
CM and insomnia disorder.
We excluded any females with an unstable medi-
cal condition (including other sleep disorders) which 
required immediate treatment according to the study 
physician, or was judged to interfere with the proto-
col. Similarly, individuals with any psychiatric condi-
tion (self-reported or assessed by clinical interview) 
judged to interfere with the study protocol including 
substance abuse, psychotic disorder, cognitive disorder, 
current suicidal ideation, or any uncontrolled psychiat-
ric conditions that required immediate treatment were 
excluded from this study. Regular users of illegal sub-
stances or medications known to affect sleep as well as 
women who were pregnant or nursing were excluded.
Study Design.—We used a multiple baseline design 
(MBD) where the introduction of the intervention 
phase is staggered across different groups of individu-
als (tiers) in a time-lagged manner (see Fig. 1). Effects 
Fig. 1.—Study design. Eligible participants were randomised to one of three different groups, differing in length of baseline prior to 
the start of the intervention (dCBT-I). Pre-treatment assessment (Pre), post-treatment assessment (Post), weeks (W).
*URXS$ 3UH %DVHOLQH Z G&%7, 3RVW*URXS% 3UH %DVHOLQHZ G&%7, 3RVW*URXS& 3UH %DVHOLQHZ G&%7, 3RVW5DQGRPL]DWLRQ
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related to the intervention are inferred when a change 
in the dependent variable coincides with the introduc-
tion of the intervention, and this relationship is repli-
cated across the subsequent tiers. MBD was selected 
for this study to efficiently inform feasibility, while 
 simultaneously assessing potential treatment effects of 
dCBT-I in CM-I. MBD has been used to test interven-
tions for both migraine58 and insomnia.59
Procedures.—The study was approved by the 
Rush University Medical Center Institutional Review 
Board. Upon expressing interest in participating in 
this study, individuals were asked to provide informed 
consent and were assessed for eligibility. Informed 
consent was gathered in writing or by email for those 
living out of travel distance. All participants com-
pleted the ISI to confirm the presence of insomnia 
symptoms. Participants who were recruited from the 
case-controlled observational study underwent a brief  
interview to confirm eligibility. Those individuals re-
cruited prospectively were evaluated through a medi-
cal and psychiatric screening interview. Once eligibility 
was ascertained, all participants completed a baseline 
questionnaire packet sent via an online survey tool 
(Survey Monkey®). The questionnaire packet consist-
ed of several measures assessing sleep and headaches. 
Participants were then randomly assigned to 1 of 3 
baselines (see Fig. 1): Group A, consisted of a 2-week 
baseline, Group B, consisted of a 4-week baseline, and 
Group C, consisted of a 6-week baseline. A statistician 
at Rush University Medical Center not involved in the 
research study, generated a block-stratified randomiza-
tion schedule using the “rand()” function in excel. To 
avoid bias, the schedule was concealed for the research 
staff  members (MRC, HLT) that were involved in the 
screening process until the participant was deemed el-
igible and had to be notified of their randomization. 
Each participant began the baseline assessment by 
completing an electronic sleep diary, which was spe-
cifically created for the case-controlled observation-
al study.53 After completion of the baseline period, 
individuals started the 6-week dCBT-I program. We 
chose 2 weeks for the baseline length in Group A and 
a 2-week time lag for each subsequent tier, because 
MBDs require a stable baseline pattern prior to the in-
tervention and 2 weeks of sleep diary data is often cited 
in the literature as the minimum requirement to record 
a stable sleep pattern.60 After completing the baseline 
period, individuals were sent an access code for the 
dCBT-I program (see details below). During the trial, 
participants were instructed to continue with treatment 
as usual, and consult with their health care provider 
about any changes to their medication regime. About 
1 week following completion of the dCBT-I program, 
all participants were sent an email with a link to com-
plete posttreatment assessments via Survey Monkey. 
The assessment consisted of several patient-reported 
measures assessing insomnia, headaches, and treat-
ment satisfaction (see below for details). Participants 
received USD 100 for completing all study activities.
Intervention.—In this study dCBT-I (Sleepio, 
www.sleep io.com), consisted of  6 weekly sessions de-
livered over the internet by an animated virtual ther-
apist. The content included behavioral (eg, sleep re-
striction, stimulus control), cognitive (eg, putting the 
day to rest, thought restructuring, imagery, articu-
latory suppression, paradoxical intention, mindful-
ness), and relaxation strategies (progressive muscle 
relaxation and autogenic training) as well as advice 
on lifestyle and bedroom factors (sleep hygiene), 
see Table 1. The program was fully automated, 
and personally tailored using dynamic algorithms 
applied to the data gathered throughout the program 
with questionnaires and sleep diaries. More detail 
about the intervention can be found in the original 
publication.61
To access dCBT-I, participants were provided with 
a voucher access code with instructions on how to 
log onto the website. Sessions could be completed at 
Table 1.—Outline of  Intervention Sessions
Session Description
1 Formulation, goal setting, diary keeping, 
 motivational contract
2 Sleep hygiene (lifestyle & bedroom), Progressive 
relaxation, thought checker
3 Sleep hygiene (schedule), stimulus control, sleep 
restriction
4 Depending on priorities: Cognitive restructure, 
autogenic training, imagery, mindfulness, 
 paradoxical intention
5
6 Review goals, reinforce motivation
Headache 5
the individual’s own pace in a maximum of 12 weeks. 
The shortest interval between individual sessions was 
7 days; thus, the program could be completed between 
5 and 12  weeks. There was no face-to-face contact 
throughout the intervention and all treatment ses-
sions, support, and reminders were provided through 
the system. The online platform was accessible to each 
participant any time of the day or night. The partic-
ipants were encouraged, however, to contact the re-
search team if  they were experiencing any difficulties 
related to the trial, and the program support team if  
they were experiencing any technical issues. The re-
search team initiated contact during the intervention 
phase only when it was clear that the participant was 
approaching the deadline to complete the treatment 
within the 12 weeks (accounting for the need to have at 
least 7 days between each treatment session), or when 
there were concerns about the participant’s safety (eg, 
indicating increased daytime sleepiness on their diary). 
The intervention was tested in its original format and 
no adaptations for this population were made to the 
intervention at this stage.
Measures.—Patient Satisfaction Questionnaire 
Short Form (PSQSF).—The PSQSF was originally 
created to measure patient satisfaction for sleep apnea 
services. The item “how satisfied are you with the care 
you received from the sleep center?” was amended to 
“how satisfied are you with the care you received from 
Sleepio for your insomnia?” and responses were indi-
cated on a 5-point scale from very satisfied to very dis-
satisfied. Open box responses were also added to the 
questionnaire for participants to indicate areas they 
liked/disliked about the program after completing the 
intervention
Insomnia Severity Index.—The ISI is a brief 5-item 
scale that measures insomnia severity.62,63 It has adequate 
internal consistency with evidence supporting concur-
rent, predictive, and content validity.62 The ISI was used 
both as a screening tool and a postintervention measure.
Sleep Diaries.—Prospective daily sleep diaries were 
used to assess self-reported sleep patterns and ratings of 
sleep quality. Sleep diaries have been shown to be a reli-
able and valid index of insomnia64 and have been used 
as an outcome measure in efficacy studies on insomnia 
(eg, Edinger et al65). During the baseline and interven-
tion phases prospective self-report data were collected 
using online sleep diaries both based on the consensus 
sleep diary66 which consisted of questions regarding 
bed time, sleep onset latency, wake time after sleep 
onset, rise time, and ratings of sleep quality. From these 
variables, we were able to deduce total sleep time and 
sleep efficiency (ratio between total sleep time and time 
in bed). The sleep diary for the baseline phase was pro-
vided through a portal developed specifically for the 
case-control observational study53 and the sleep diary 
during the intervention was provided through the in-
tervention interface.
The Migraine Disability Assessment (MI-
DAS)67.—The MIDAS was used to measure migraine 
impairment, frequency, and severity pre- and postin-
tervention. The 5-item questionnaire assesses the num-
ber of days of impairment in different domains (eg, 
work, school, household) over the previous 3 months. 
The psychometric properties of the scale are good.67
Benchmarks.—As outlined by Leon and colleagues68 
proof-of-concept studies should not test formal outcome 
hypotheses, but focus on gathering data needed to in-
form the design of a subsequent full-scale randomized 
controlled trial (RCT). Feasibility, acceptability, and pre-
liminary efficacy were measured to achieve this aim.
Feasibility (Benchmark 1).—Completion of dCBT-I 
was used as a marker of feasibility and defined as com-
pleting all 6 sessions within the maximum 12-week 
 period. Our benchmark for feasibility was ≥90%.
Acceptability (Benchmark 2).—A version of the 
Patient Satisfaction Questionnaire Short Form PSQSF 
adapted for use in the CM population69 was used to 
assess patient’s treatment satisfaction as it pertains 
to the treatment protocol. Treatment satisfaction was 
operationalized, as the percentage of participants indi-
cating to be “satisfied” or “very satisfied” with the in-
tervention on the PSQSF (1-item). Our benchmark for 
acceptability of dCBT-I was set to ≥80% of the sam-
ple reporting satisfaction with treatment. We moni-
tored the responses in the open boxes of the PSQSF for 
any reported side effects associated with the treatment.
Preliminary Efficacy (Benchmark 3).—Preliminary 
efficacy was assessed primarily by number of individ-
uals showing a clinically meaningful difference in in-
somnia severity at the end of treatment. Improvements 
in insomnia severity were measured using the ISI and 
defined as >7 points change in the ISI total score, 
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which has been established as a valid cutoff  depicting 
marked clinical improvement.70 Our benchmark for 
preliminary efficacy was at least 50% of participants 
demonstrating a clinically meaningful change in in-
somnia severity from baseline-to-posttreatment. The 
benchmark of 50% was selected based on previous 
studies reporting response rates between 39 and 65% 
after digital CBT-I.71,72
Data Preparation and Statistical Analysis.—For 
each benchmark, we calculated the percentage of par-
ticipants meeting those prespecified criteria. We also 
calculated intention to treat (ITT) rates based on all 
individuals who were randomized, as well as those 
who started and finished the program as per protocol 
[PP]). Qualitative data from open-box responses on the 
adapted PSQF were also analyzed using content anal-
ysis73 to capture rich data on treatment acceptability 
(reported in Supporting Information 1). In addition 
to our benchmarks, we analyzed pre-to-post change in 
insomnia severity and headache impairment, severity, 
frequency, and reported confidence intervals for the 
difference. Means and standard deviations are report-
ed where appropriate. As exploratory analysis, we con-
ducted a visual analysis of the multiple baseline data 
(reported in more detail in the Supporting Information 
2) and a mixed model analysis to test the effects of the 
intervention (details reported in the Supporting Infor-
mation 3). Since this was a feasibility study, no formal 
statistical inferences were conducted for all analyses. 
Instead, results focus on estimating effect sizes and 
confidence intervals. There was no missing data for the 
benchmark data (feasibility, acceptability of treat-
ment, and improvement in insomnia) or for the mi-
graine data (secondary analysis). For the baseline 
phase, there were no missing sleep diary days. For the 
treatment phase, the average was 2.85  days missing 
(SD = 9.54, max = 44). Only 3 participants had more 
than 5 missing days in total, and the missing days were 
from instances where the continuation of the interven-
tion was temporarily interrupted for personal reasons. 
Missing data on individual days/nights on the diary are 
controlled for within the mixed model analysis.
RESULTS
Participant Characteristics.—About 193 individuals 
were evaluated for study eligibility; 149 did not con-
tinue past the initial telephone screening interview, 
see Figure 2. The most frequent reasons for exclu-
Fig. 2.—CONSORT 2010 flow diagram.
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sion (n = 114) at the telephone stage were not meeting 
criteria for CM (n  =  73, 64%), or insomnia (n  =  22, 
19.3%), or presenting with an unstable medical condi-
tion (n = 5, 4.4%). A total of 44 participants complet-
ed the in-person screening, after which 2 were exclud-
ed. These 2 individuals were excluded because of not 
meeting criteria for CM (n = 1) and suspicion of de-
layed sleep phase disorder (n = 1). Participant charac-
teristics are reported in Table 2.
Primary Analysis: Benchmarks.—Benchmark 
1-Feasibility.—Out of 42 randomized participants, only 
39 participants started the program. In total, 35 complet-
ed the program within the 12 weeks provided, thus, the 
PP completion rate was 89.7% (35/39). Based on inten-
tion-to-treat (ITT) analysis, 35 of the initial 42 who were 
randomized completed dCBT-I, thus, the ITT comple-
tion rate was 83.3%, see Table 3. Both rates were some-
what under our benchmark of ≥90% completion rate. 
Reasons for not completing the program were inability 
to complete because of time commitments, and misun-
derstanding of requirement to complete all 6 sessions.
Benchmark 2-Acceptability.—Out of the 35, who 
completed dCBT-I and rated their satisfaction 
with the treatment, 33 (94.3%) reported being satis-
fied (n = 15) or very satisfied (n = 18) with treatment, 
thus, our benchmark for acceptability (≥80% satisfied 
with treatment) was met, see Table 2. The remaining 2 
individuals rated that they felt neutral about the pro-
gram. We were not able to collect satisfaction from 
data from non-completers. The ITT acceptability rate 
(% satisfied of those randomized) was 78.6% (33/42). 
The PSQSF questionnaire also provided participants 
with the opportunity to detail specific likes and dislikes, 
which are reported in detail in Supporting Information 
1. Briefly, 2 raters (MRC and HLT) reviewed the con-
tent and independently assigned a code to each data 
point. Content analysis revealed that the majority of 
individuals liked the content of the program and there 
was no overwhelming dislike of the program. The three 
most frequently rated likes were “content of the pro-
gram” (n = 17), “efficacy of the treatment” (n = 12), and 
“accessibility/convenience/ease” (n = 12). The most fre-
quently noted dislike was “configurations of the inter-
face/computer program/app” (n = 10)). This included 
comments such as “get an app for android,” or “the 
constant motion of the animation.”
We recorded spontaneous reporting of adverse 
events through the information in the open-response 
text box on the posttreatment (eg, feeling nauseous 
from the motion in the animation). No serious adverse 
events deemed related to the intervention were reported 
by the participants.
Benchmark 3-Efficacy.—Of the 35 individuals who 
completed the treatment program (per protocol), 23 
Table 2.—Participant Characteristics of  42 Randomised 
Participants
 
N(%)/Mean 
(Range or SD)
Age 42.0 (range 22-80)
Race  
Black or African American 6 (14.3%)
White 36 (85.7%)
Ethnicity  
Hispanic 1 (2.4%)
Non-Hispanic 41 (97.6%)
Employment  
Full-time employment (≥32 hours/week) 15 (35.7%)
Part-time employment (<32 hours/week) 12 (28.6%)
Unemployed 0
Full-time caregiver 1 (2.4%)
Retired 5 (11.9%)
Student 2 (4.8%)
Disabled/too ill to work 7 (16.7%)
Education (years) 16.6 (SD 2.7)
Marital status  
Single 8 (19.0%)
In relationship but not cohabiting 6 (14.3%)
Living with spouse/life partner 25 (59.5%)
Divorced or separated 2 (4.8%)
Widowed 1 (2.4%)
Insomnia Severity Index score at baseline 18.4 (SD 3.7)
Duration of chronic migraines in years 8.1 (SD 8.0)
Table 3.—Benchmarks and Results
  Benchmark Result
Feasibility ≥90% 89.7% for PP (83.3% for ITT)
Acceptability ≥80% 94.3% for PP (78.6% for ITT)
Clinical 
 improvement, 
ISI change >7
≥50% 65.7% for PP (54.8 for ITT)
ISI = Insomnia Severity Index; ITT = intention to treat; PP = 
per protocol.
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(65.7%) showed a clinically meaningful difference as 
indicated by a change from baseline >7 points on the 
ISI (responders). The ITT response rate was 54.8% 
(23/42). Both values (per protocol [PP] and ITT) were 
higher than our target benchmark of 50% response 
rate, see Table 3. Additionally, 16 (45.7%) were classi-
fied as remitters, which was defined as an ISI posttreat-
ment score <8.
Secondary Analysis: Improvements in Sleep and 
 Migraines.—Insomnia severity was reduced at post- 
treatment (ISI mean = 7.7, SD = 4.1) compared to base-
line (ISI mean = 17.6, SD = 4.0, mean difference = −9.9; 
95% CI = −11.7; −8). At baseline, the average total MI-
DAS score was 28.7 (SD = 19.5) and at posttreatment this 
reduced to 22.4 (SD = 17.8), mean difference = −6.3 (95% 
CI = −12.3; −0.02). We used the frequency and severity 
items from the MIDAS to report changes in frequency 
and severity. The migraine frequency was reduced from 
21 (SD  =  7.0) to 18.4 (SD  =  8.7) headache days per 
month at posttreatment (mean difference = −2.6, 95% 
CI: −4.58; −0.7). At posttreatment, the severity of mi-
graines had reduced (on a scale of 0-10) from 6.5 (SD 
1.4) to 5.4 (SD 1.3), mean difference = 1.1, 95% CI: −1.5; 
−0.6) with lower scores indicating less severe migraines. 
At posttreatment, 12 individuals of the 35 who had com-
pleted the treatment had reverted to episodic migraine 
(34.3% of the sample; ITT  =  12/42  =  28.6%) and no 
longer met the duration criteria for CM.
Exploratory Analysis: Visual Analysis and Interrupt-
ed Time Series Linear Mixed Model Analysis of the 
Multiple Baseline Data.—We visually analyzed the 
sleep efficiency data across the baseline and treat-
ment phases, in order to determine whether a change 
in sleep efficiency was associated with the start of the 
intervention. To accomplish this, 2 raters (HT and AL) 
reviewed graphical representation of sleep efficiency 
changes across the baseline and the intervention phases 
for each participant (see Fig. 3 as an example). Each 
Fig. 3.—Example multiple baseline graph, where the change in mean sleep efficiency (dashed line) in all graphs increased with the 
start of the intervention (according to both raters). The individual in the top graph was randomized to 2-weeks baseline, the individual 
in the middle graph to 4-weeks baseline (note, this participant started the intervention with a slight delay), the individual in the bottom 
graph was randomized to the 6-week baseline.
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rater evaluated whether there was a change in the 
mean, trajectory and night-to-night variability of sleep 
efficiency that coincided with the start of the inter-
vention. Inter-rater reliability (IRR) was evaluated by 
calculating kappa values for each variable. The IRR 
varied between 0.5 and 0.8, indicating a moderate to 
substantial agreement between the 2 raters. The raters 
agreed that there was a change in the mean sleep effi-
ciency associated with the start of the intervention in 
83% of participants; a change in the sleep efficiency 
trajectory in 33% of participants; and a change in the 
night-to-night variability in 41% of the participants 
(further details on the visual analysis and results are 
provided in the Supporting Information 2).
In addition to the visual analysis, we also con-
ducted a time series linear mixed model. The linear 
mixed model allowed us to estimate the effect of the 
intervention for each participant in an interrupted time 
series context, taking into account individual differ-
ences in sleep efficiency and responses to the interven-
tion. Our model was:
where Y
is
 is the ith sleep efficiency score for participant 
S, S0s represents the random intercept for each par-
ticipant, S, and S1s is the random slope indicating the 
individual response to the immediate introduction of 
the intervention. The other terms represent the fixed 
effects described for a standard interrupted time series 
analysis. Although the data are a MBD, the continuous 
time covariate accounts for different baseline lengths.
The time series linear mixed model revealed 
an influence of Time (b  =  0.12, 95% CI [0.05, 0.18], 
SE  =  0.04), indicating an increase in sleep efficiency 
with time. There was also an effect of intervention, 
(b = −4.57, [−9.06, −0.08], SE = 2.29), which showed 
a decrease in sleep efficiency with immediate intro-
duction of the intervention. The interaction between 
time and the intervention, however, showed an in-
crease in sleep efficiency with time after the interven-
tion (b  =  0.20, [0.07, 0.33], SE  =  0.07). Finally, the 
quadratic interaction term did not show a large influ-
ence on sleep efficiency, (b = −0.001, [−0.002, −0.001], 
SE = 0.00). Additional information about the model is 
presented in Supporting Information 3.
DISCUSSION
This proof-of concept study has highlighted that 
dCBT-I could be an appropriate treatment for individ-
uals with CM-I. The results demonstrate that the ma-
jority of our benchmarks were met (2 out of 3, and 1 
just marginally under the benchmark for our PP rates). 
While our ITT results were less promising (according 
to the ITT rates 1 out of 3 benchmarks met), however, 
this was because of the higher dropout rates prior to 
treatment. We, therefore, still conclude that dCBT-I is a 
feasible treatment for females with CM-I. A follow-up 
RCT is appropriate needed to determine the efficacy.
The majority of the participants (89.7%) were able 
to complete the program within the designated time-
frame. The ITT completion rate was lower (83%), how-
ever, these dropouts occurred prior to the start of the 
intervention, so we believe there is no need to refine 
the intervention for this population. The reasons for 
non-completion did not seem to be related to any spe-
cific aspect of the dCBT-I program. The number of 
individuals who did not complete the program (n = 4, 
10%) is lower than those reported in the Smitherman 
et al. study (n = 7, 22%), in which the authors tested a 
3-session face-to-face intervention for insomnia which 
included stimulus control and sleep restriction. This is 
surprising, considering digital therapies are typically 
associated with higher dropout rates (around 24%39). 
The reason for our lower dropout rates might be the 
increased contact with participants during the baseline 
phase prior to treatment initiation.
The intervention was also rated as acceptable by 
the majority of the sample (94.3%). These findings rep-
licate previous reports of high satisfaction ratings of 
other digital CBT-I platforms.74-77 The treatment was 
rated highly by the majority of participants, and this 
was corroborated by qualitative reports. For example, 
34% of the participants spontaneously cited accessibil-
ity/convenience/ease of the intervention as advantages. 
By comparison, none of the participants felt the inter-
vention was too burdensome. This aligns with our pre-
diction that such a minimal contact therapy would be 
ideal for patients who experience CM.
The intervention was also associated with clini-
cally meaningful response to treatment (indicated by 
>7 point change in insomnia severity) in 65.7% of the 
sample. About half  of  the sample’s insomnia remitted 
Y
is
= (훽0+S0s)+훽1Ti+ (S1s+훽2I )i+훽3TI i+훽4TI
2
i
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to nonclinical levels (ISI posttreatment score <8). This 
is comparable to remission rates published from re-
search in digital CBT-I with insomnia and other phys-
ical comorbidities.77 Our remission rates are slightly 
higher than rates reported in a meta-analysis of  RCTs 
evaluating face-to-face CBT-I trials with physical or 
mental comorbidities (average 36% remission rate),29 
however, it is important to note that the meta-anal-
ysis also included the PSQI remission rates, so these 
numbers are not entirely comparable. Our results for 
insomnia improvements support previous findings 
on treating insomnia in individuals with CM using 
face-to-face interventions.33,34 In Smitherman and col-
leagues34 trial, the intervention was associated with sig-
nificantly greater improvement in sleep efficiency and 
sleep quality, which we replicated in terms of changes 
in insomnia severity and daily sleep efficiency (using 
both the visual analysis and the linear mixed model 
analysis). Calhoun and Ford reported remission to ep-
isodic migraine was substantially greater in the treat-
ment than in a placebo control condition (35 vs 0%), 
which is comparable to our results (34%). Six weeks 
after completing the behavioral treatments for insom-
nia, the authors reported a reduction in headache 
frequency twice the effect seen in the placebo control 
condition, which included lifestyle changes only (48% 
reduction vs 25% reduction). DCBT-I in our study was 
associated with slightly less improvement in headache 
impairment (22% reduction in level of  impairment) 
and frequency (12% reduction in frequency). These 
differences may be due to the digital medium, and less 
flexibility within this program to personalize the ther-
apeutic instructions and make them relevant to the 
migraine patient compared to face-to-face treatment. 
These changes are also lower than those associated 
with interventions targeting migraine specifically via 
CBT for migraine pain,78 Botox (OnabotulinumtoxinA 
Injection),79 or other prophylactic migraine medi-
cation80 (between 20 and 40% reduction in migraine 
frequency). Future, fully powered efficacy studies will 
need to establish more accurate rates of  remission as-
sociated with dCBT-I.
Together, our results are promising; demonstrat-
ing cognitive behavioral-based strategies for insomnia 
is an effective strategy for improving both insomnia 
and potentially as an adjunct treatment for migraines 
in this population. Furthermore, the results support 
the evaluation of  treatment efficacy through a larger 
RCT without significant adaptations to the digital 
program.
A larger RCT employing more scientific rigor is 
needed to evaluate dCBT-I against some form of con-
trol group/placebo condition. For this proof-of-con-
cept study, we deliberately selected a MBD to provide 
at least some preliminary level of control. MBDs are 
ideal for smaller feasibility studies as groups who begin 
the intervention can act as a control for the group who 
have already started the intervention. The visual analy-
sis and linear mixed modeling gave us some indication 
that dCBT-I might be effective in this population and 
encourages us to explore this hypothesis in a well-con-
trolled follow-up study.
The results need to be considered alongside the 
study limitations. First, we measured treatment ac-
ceptability using a single item, which compared 
to multi-item scales is less reliable and sensitive to 
change. Additionally, we limited our recruitment to 
individuals with CM, and therefore, our data cannot 
be extrapolated to episodic migraines or other types 
of  headache disorders. However, the burden of  CM 
is greater and sleep problems are more prevalent in 
CM patients compared to those with episodic mi-
graines44 supporting a more urgent need to evaluate 
treatments in this group. There are speculations that 
poor sleep might play a role in the chronification of 
migraines, but unfortunately, longitudinal studies are 
lacking. Future studies will need to explore the pos-
sibility that dCBT-I could counteract these effects, 
and potentially reduce the number of  transitions to 
CM. Another limitation of  this study is the lack of 
a control group receiving no treatment. However, as 
mentioned above, the scientific rigor and control pro-
vided through the MBD was sufficient for this type of 
feasibility study. For changes in headaches, we used 
the frequency and severity items on the MIDAS, but 
acknowledge that a headache diary at posttreatment 
would have been beneficial for more accurate estima-
tion of  these variables. We also did not take a formal 
measure of  adverse events. Our results may also not 
be entirely generalizable considering (1) the inclusion 
of  only females and (2) high levels of  education in our 
sample, however, this is typical of  research samples 
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in general, and those including individuals with 
insomnia and CM. Finally, we only measured sleep 
patterns subjectively; future studies should include 
objective measurements such as wrist actigraphy or 
polysomnography.
In conclusion, we are encouraged by our results 
on feasibility, acceptability, and preliminary efficacy, 
and believe that dCBT-I is appropriate for this pop-
ulation. An RCT to demonstrate treatment efficacy 
in this group of  patients will be needed before use 
in the clinical pathway for patients with CM can be 
recommended.
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SUPPORTING INFORMATION
Additional supporting information may be found 
in the online version of this article at the publisher’s 
web site.   
